SCHEMBL11925829

SCHEMBL11925829

Cc1nnc(-c2ccn3c(-c4cccc(N)c4)cnc3c2)o1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.68
FGFR3 P22607 5/20 0.68
FLT3 P36888 5/20 0.47
MECP2 P51608 1/20 0.46
GABRG2 P18507 2/20 0.44
GABRB3 P28472 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRA1 P14867 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA2 P47869 1/20 0.43
ATAD2 Q6PL18 1/20 0.43
DYRK3 O43781 1/20 0.41
CCNT1 O60563 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK9 P50750 1/20 0.41
CDK5 Q00535 1/20 0.41
DYRK1A Q13627 1/20 0.41
CDK5R1 Q15078 1/20 0.41
DYRK2 Q92630 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14143928 0.86 KDR (0.52) KDRFGFR3FLT3MECP2GABRG2
SCHEMBL11929419 0.81 FGFR3 (1.00) KDRFGFR3
SCHEMBL10175034 0.80 KDR (0.52) KDRFGFR3FLT3
SCHEMBL3910760 0.80 MECP2 (0.69) MECP2ATAD2
SCHEMBL11925485 0.79 GABRG2 (0.66) KDRFGFR3FLT3GABRG2GABRB3
SCHEMBL13336369 0.79 KDR (0.75) KDRFGFR3FLT3GABRG2GABRB3
SCHEMBL14144073 0.78 KDR (0.54) KDRFGFR3FLT3GABRG2GABRB3
SCHEMBL13574256 0.77 KDR (0.64) KDRFGFR3FLT3GABRG2GABRB3
SCHEMBL14143927 0.77 FLT3 (0.49) KDRFGFR3FLT3GABRG2GABRB3
SCHEMBL13574183 0.77 KDR (0.56) KDRFGFR3FLT3GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300465-B1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LTD (GB) 2019-04-17 EP disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ABL1, ERBB2, RET KDR 50/4885FGFR3 82/4885FLT3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.